All In Biotech

Drug Trial Radar · NCT04921358

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Randomized Phase 3 Study of Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Progressed on or After Platinum-Based Chemotherapy and Anti-PD-(L)1 Antibody

Last checked: Nov 19, 2026Latest source record: Jun 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 377 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

377

Actual

Start

Jul 27, 2021

Primary completion

Dec 20, 2023

Study completion Dec 20, 2023

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Jun 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the efficacy and safety of tislelizumab in combination with sitravatinib compared to docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) who experienced disease progression following platinum-based chemotherapy and anti-programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) antibody treatment, with the anti-PD-(L)1 antibody administered either in combination with or sequentially before or after the platinum-based chemotherapy.

Conditions

  • Non-Small Cell Lung Cancer (NSCLC)

Interventions

  • TislelizumabDrug

    200 mg intravenously once every 3 weeks

  • DocetaxelDrug

    75 mg/m\^2 intravenously once every 3 weeks

  • SitravatinibDrug

    100 mg orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Until the study completion data cut-off date of December 20, 2023, or the last available date confirming participants were alive (a median follow-up of approximately 8 months).
  2. Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)Time frame: Until the study completion data cut-off date of December 20, 2023, or the last available date confirming participants were alive (a median follow-up of approximately 8 months).

Locations

61 sites in 2 countries. Site status is shown where the registry gives one.

  • Blacktown Cancer and Haematology Centre

    Blacktown, New South Wales, Australia

  • Campbelltown Hospital

    Campbelltown, New South Wales, Australia

  • The Tweed Valley Hospital

    Cudgen, New South Wales, Australia

  • St George Hospital

    Kogarah, New South Wales, Australia

  • Pindara Private Hospital

    Benowa, Queensland, Australia

  • Cancer Research South Australia

    Adelaide, South Australia, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • St Vincents Hospital Melbourne

    Fitzroy, Victoria, Australia

  • Sunshine Hospital

    St Albans, Victoria, Australia

  • Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital

    Hefei, Anhui, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Xinqiao Hospital Affiliated to the Army Medical University

    Chongqing, Chongqing Municipality, China

  • Daping Hospital, Third Military Medical University

    Chongqing, Chongqing Municipality, China

  • Fujian Provincial Hospital

    Fuzhou, Fujian, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • Cancer Center of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Guangdong Provincial Peoples Hospital

    Guangzhou, Guangdong, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Cancer Hospital of Shantou University Medical College

    Shantou, Guangdong, China

  • Cancer Hospital Chinse Academy of Medical Sciences, Shenzhen Center

    Shenzhen, Guangdong, China

  • The Peoples Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi, China

  • The Tumor Hospital Affiliated to Guangxi Medical University

    Nanning, Guangxi, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The First Peoples Hospital of Chenzhou

    Chenzhou, Hunan, China

  • The Second Hospital, University of South China

    Hengyang, Hunan, China

  • Changzhou No Peoples Hospital, the Affiliated Hospital of Nanjing Medical University Branch Cheng

    Changzhou, Jiangsu, China

  • Nanjing First Hospital

    Nanjing, Jiangsu, China

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, China

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.